Round and round, we go

After Tandem and Dexcom reported stronger than anticipated second quarter growth everyone just assumed that Insulet would follow suit. Shares of the company were up strong today over 4%. Well so much for assumptions as Insulet has revised their full year guidance downward. Per the earnings press release;

“For the year ending December 31, 2018, the Company is revising its revenue guidance to a range of $547 to $562 million, representing growth of approximately 18% to 21% (previously $565 to $580 million), compared to 2017 revenue of $463.8 million. The Company is revising its expectations for its International Omnipod . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.